Unknown

Dataset Information

0

Cytochrome P450 2D6 and homeobox 13/interleukin-17B receptor: combining inherited and tumor gene markers for prediction of tamoxifen resistance.


ABSTRACT: Genetic variation in cytochrome P450 2D6 (CYP2D6) and the gene expression ratio of the homeobox 13 (HOXB13) to interleukin-17B receptor (IL17BR) are associated with tamoxifen resistance. We sought to determine the combined effect of inherited (CYP2D6) and somatic (HOXB13/IL17BR) gene variation in tamoxifen-treated breast cancer.Retrospective analysis of women with node-negative breast cancer randomized to receive 5 years of tamoxifen (North Central Cancer Treatment Group 89-30-52). CYP2D6 metabolism (extensive or decreased) was based on CYP2D6*4 genotype and presence/absence of a CYP2D6 inhibitor. Reverse transcription-PCR profiles for HOXB13 and IL17BR and the cut point separating patients into high- and low-risk categories according to disease-free survival (DFS) were used. A risk factor (CYP2D6:HOXB13/IL17BR) representing the four categories of combining CYP2D6 metabolism (extensive or decreased) and HOXB13/IL17BR (low or high) was created. The association between CYP2D6:HOXB13/IL17BR and DFS and overall survival (OS) was assessed using the log-rank test and proportional hazards modeling.CYP2D6 metabolism and HOXB13/IL17BR gene ratio was available in 110 of 160 (69%) patients. The combined CYP2D6:HOXB13/IL17BR risk factor was significantly associated with DFS (log-rank P = 0.004) and OS (P = 0.009). Relative to women with extensive CYP2D6 metabolism and low HOXB13/IL17BR, those with either decreased metabolism or a high HOXB13/IL17BR ratio had significantly worse OS (adjusted hazard ratio, 2.41; 95% confidence interval, 1.08-5.37; P = 0.031), whereas women with both decreased metabolism and high HOXB13/IL17BR ratio had the shortest survival (adjusted hazard ratio, 3.15; 95% CI, 1.17-8.52; P = 0.024).An index composed of inherited (CYP2D6) and tumor (HOXB13/IL17BR) gene variation identifies patients with varying degrees of resistance to tamoxifen.

SUBMITTER: Goetz MP 

PROVIDER: S-EPMC2596658 | biostudies-literature | 2008 Sep

REPOSITORIES: biostudies-literature

altmetric image

Publications

Cytochrome P450 2D6 and homeobox 13/interleukin-17B receptor: combining inherited and tumor gene markers for prediction of tamoxifen resistance.

Goetz Matthew P MP   Suman Vera J VJ   Couch Fergus J FJ   Ames Matthew M MM   Rae James M JM   Erlander Mark G MG   Ma Xiao-Jun XJ   Sgroi Dennis C DC   Reynolds Carol A CA   Lingle Wilma L WL   Weinshilboum Richard M RM   Flockhart David A DA   Desta Zeruesenay Z   Perez Edith A EA   Ingle James N JN  

Clinical cancer research : an official journal of the American Association for Cancer Research 20080901 18


<h4>Purpose</h4>Genetic variation in cytochrome P450 2D6 (CYP2D6) and the gene expression ratio of the homeobox 13 (HOXB13) to interleukin-17B receptor (IL17BR) are associated with tamoxifen resistance. We sought to determine the combined effect of inherited (CYP2D6) and somatic (HOXB13/IL17BR) gene variation in tamoxifen-treated breast cancer.<h4>Experimental design</h4>Retrospective analysis of women with node-negative breast cancer randomized to receive 5 years of tamoxifen (North Central Can  ...[more]

Similar Datasets

| S-EPMC4025842 | biostudies-literature
| S-EPMC3322812 | biostudies-literature
| S-EPMC4717011 | biostudies-literature
| S-EPMC8486079 | biostudies-literature
| S-EPMC9579386 | biostudies-literature
| S-EPMC6339413 | biostudies-literature
| S-EPMC6618095 | biostudies-literature
| S-EPMC8452298 | biostudies-literature
| S-EPMC6806731 | biostudies-literature
| S-EPMC4752389 | biostudies-literature